Cook General Biotechnology

FierceBiotech | February 10, 2020

A £550 million ($711 million) deal to find new homes for Neil Woodford’s biotech holdings has collapsed, raising the prospect that stakes in companies including Immunocore will be auctioned off for knock-down prices. Woodford became a go-to source of money for private British biotechs in the years after he left Invesco to set up his own fund. However, the illiquid nature of Woodford’s holdings in such companies became a problem as more and more investors began taking money out ...

Industrial Impact

Quantum Genomics | December 06, 2021

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Medical

Businesswire | August 03, 2023

A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery. Reported in Cell Chemical Biology, researchers from Promega Corporation and WuXi AppTec generated new chemical probes from molecules identified through a DEL screen. This research opens new opportunities to develop novel NanoBRET Target Engagement Assays aimed at many understudied classes of proteins, rapidly accelerating “h...

Cell and Gene Therapy

Y-Biologics | November 23, 2020

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...